Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Sold by Hillsdale Investment Management Inc.

Hillsdale Investment Management Inc. lowered its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 42.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 372 shares of the medical research company’s stock after selling 280 shares during the quarter. Hillsdale Investment Management Inc.’s holdings in Thermo Fisher Scientific were worth $194,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in the business. Geo Capital Gestora de Recursos Ltd boosted its stake in shares of Thermo Fisher Scientific by 6,455.6% in the fourth quarter. Geo Capital Gestora de Recursos Ltd now owns 4,130 shares of the medical research company’s stock worth $2,149,000 after buying an additional 4,067 shares during the last quarter. Runnymede Capital Advisors Inc. acquired a new stake in shares of Thermo Fisher Scientific during the 4th quarter worth approximately $78,000. Mizuho Securities USA LLC boosted its holdings in Thermo Fisher Scientific by 46.4% during the fourth quarter. Mizuho Securities USA LLC now owns 36,252 shares of the medical research company’s stock worth $18,859,000 after buying an additional 11,482 shares in the last quarter. Virtu Financial LLC increased its holdings in Thermo Fisher Scientific by 1,058.4% in the fourth quarter. Virtu Financial LLC now owns 11,955 shares of the medical research company’s stock valued at $6,219,000 after buying an additional 10,923 shares in the last quarter. Finally, Quantbot Technologies LP boosted its stake in shares of Thermo Fisher Scientific by 813.5% during the 4th quarter. Quantbot Technologies LP now owns 19,092 shares of the medical research company’s stock worth $9,932,000 after acquiring an additional 17,002 shares in the last quarter. 89.23% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on TMO shares. Morgan Stanley upped their price target on Thermo Fisher Scientific from $647.00 to $678.00 and gave the stock an “overweight” rating in a report on Friday, January 31st. Wells Fargo & Company lifted their price target on shares of Thermo Fisher Scientific from $660.00 to $680.00 and gave the company an “overweight” rating in a research note on Friday, January 31st. StockNews.com upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Tuesday, January 14th. Bank of America cut their target price on shares of Thermo Fisher Scientific from $675.00 to $660.00 and set a “buy” rating for the company in a research note on Friday, December 13th. Finally, Royal Bank of Canada set a $693.00 price objective on Thermo Fisher Scientific in a report on Friday, January 31st. Four analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $653.23.

Insider Transactions at Thermo Fisher Scientific

In other news, EVP Gianluca Pettiti sold 300 shares of the business’s stock in a transaction dated Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total value of $175,677.00. Following the completion of the sale, the executive vice president now directly owns 16,363 shares of the company’s stock, valued at approximately $9,582,009.17. The trade was a 1.80 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Michael A. Boxer sold 3,775 shares of Thermo Fisher Scientific stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $532.52, for a total value of $2,010,263.00. Following the transaction, the senior vice president now directly owns 10,816 shares in the company, valued at approximately $5,759,736.32. This trade represents a 25.87 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 23,900 shares of company stock valued at $13,106,062. 0.34% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Stock Up 0.5 %

Thermo Fisher Scientific stock opened at $520.25 on Tuesday. The firm has a market capitalization of $196.27 billion, a P/E ratio of 31.47, a P/E/G ratio of 2.99 and a beta of 0.79. The stock’s fifty day simple moving average is $545.44 and its 200-day simple moving average is $554.91. Thermo Fisher Scientific Inc. has a twelve month low of $493.30 and a twelve month high of $627.88. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Thursday, January 30th. The medical research company reported $6.10 EPS for the quarter, topping analysts’ consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. As a group, equities analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, April 15th. Shareholders of record on Friday, March 14th will be paid a $0.43 dividend. The ex-dividend date is Friday, March 14th. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. This represents a $1.72 dividend on an annualized basis and a yield of 0.33%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.41%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.